BioSpace News Archive

Shasqi, Inc. announced the formation of its Scientific Advisory Board composed of leaders with decades of experience in oncology drug development and translational research.

Austrianova and ProAgni announced today the signing of a licensing and manufacturing agreement that foresees an intensification of joint activities between the two companies in the area of development and commercialization of shelf stable probiotic additives for cattle feed as well as for other farm animals.

The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research and Ferrer has been included by the World Health Organization in its List of Essential Medicines.

Sapient, a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis, announced that its high complexity CLIA laboratory has been awarded accreditation from the College of American Pathologists (CAP).

Alimera Sciences, Inc. announces that it will report second quarter financial results on August 10, 2023, prior to the market open.

ABM Therapeutics (ABM) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310, a novel small molecule BRAF inhibitor developed by the company, for the treatment of patients with glioblastoma (GBM) bearing BRAF V600 mutation.

iRxReminder, LLC is thrilled to announce the enrollment of its first patients in the innovative NIMH-funded study, the TDtect™ Diagnostic.

Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes.

Capricor Therapeutics will release its financial results for the second quarter ended June 30, 2023, after the market close on Monday, August 7, 2023.

Roivant announced that it will redeem all of its outstanding public warrants and private placement warrants to purchase Roivant’s common shares pursuant to its Warrant Agreement dated September 30, 2021 with Equiniti Trust Company, LLC as successor warrant agent, that remain outstanding following 5:00 p.m. New York City Time on September 1, 2023 for a redemption price of $0.10 per Warrant.